Effects of raloxifene on normal breast tissue from premenopausal women

Breast Cancer Research and Treatment

Volumn 95, Issue 2, 2006, Pages 99-103

  Da Silva, Benedito Borges ^a,c   Soares Lopes, Ione Maria Ribeiro ^a   Gebrim, Luiz Henrique ^b  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Jockey Club ^*  (Brazil)

Author keywords

Breast; Breast cancer chemoprevention; Ki 67; Normal breast; Raloxifene

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; BREAST; BREAST BIOPSY; BREAST FIBROADENOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MENSTRUAL CYCLE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STUDENT T TEST; TREATMENT OUTCOME;

ADULT; BREAST; BREAST NEOPLASMS; CELL DIVISION; DOUBLE-BLIND METHOD; EPITHELIUM; FEMALE; FIBROADENOMA; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PREMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33645211425     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9001-2     Document Type: Article

References (28)

1. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux , Dimitrov N, Atkins J: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18): 1371-1388, 1998
2. Osborne MP: Breast cancer prevention by antiestrogens. Ann NY Acad Sci 889: 146-151, 1999
3. Jordan VC: Progress in the prevention of breast cancer: concept to reality. J Steroid Biochem Mol Biol 74(15): 269-277, 2000
4. Cosman F: Selective estrogen-receptor modulators. Clin Geriatr Med 19(2): 371-379, 2003
5. Gutman M, Couillard S, Roy J, Labrie F, Candes B, Labrie C: Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 99(2): 273-278, 2002
6. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L: Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 1(1): 40, 2003
7. Actis AM, Cocca CM, Gutierrez A, Croci M, Rivera ES, Bergoc RM: Estrogen receptor profiles: changes in mouse and rat mammary tumors by treatment with selective estrogens receptors modifiers. Med Princ Pract 13(4): 220-226, 2004
8. Cummings SR, Eckert S, Krueger KA, Grady D, Powels TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiples outcomes of raloxifene evaluation. JAMA 281(23): 2189-2197, 1999
9. Cauley J, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Steppan JJ, Powles TJ, Morrow M, Costa A, Silfen Sl , Walls EL, Schmitt H, Muchmore D, Jordan VC, Ste Marie LG: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Breast Cancer Res Treat 67(2): 191, 2001
10. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SRCORE Investigators Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96(23): 1751-1761, 2004
11. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354): 296-300, 2003
12. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles TIBIS investigators First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360(9336): 817-824, 2002
13. Vogel VG, Constantino JP, Wickerham DL, Cronin WM, Wolmark N: The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 361(2): 153-159, 2002
14. Vogel VG, Constantino JP, Wickerham DL, Cronin WM: National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 9(1Pt2): 4955-5015, 2003
15. Facina G, de Lima RG, Simões MJ, Novo NF, Gebrim LH: Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cicle. Int J Gynecol Obstet 569(1): 19-24, 1997
16. de Lima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, Jordan VC, Gebrim LH: Effects of low doses tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39(7): 891-898, 2003
17. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18): 1541-1548, 1999
18. Bernardes JR Jr, Nonogaki S, Seixas MT, de Rodrigues Lima G, Baracat EC, Gebrim LH: Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynecol Obstet 67(1): 33-38, 1999
19. de Sousa JA, Seixas MT, de Lima RG, Baracat EC, Gebrim LH: Evaluation of monoclonal antibody MIB-lin the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen. Breast J 7(6): 392-397, 2001
20. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, Von Kleist S: Ki67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67(2): 421-428, 1991
21. Leers MPG, Theunissen PHMH, Ramaekers FCS, Schutte B: Multi-parameter flow cytometric analysis with detection of the Ki-67-Ag in paraffin embedded mammary carcinomas. Cytometry 27(3): 283-289, 1997
22. Rudolph P, Peters J, Lorenz D, Schmidt D, Parwaresch R: Correlation between mitotic and Ki-67 labeling in paraffin-embedded carcinoma specimens. Human Pathol 29(1): 1216-1222, 1998
23. Dardes RDM, Horiguchi J, Jordan VC: A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labeling index in women with primary breast cancer. Int J Oncol 16(1): 25-30, 2000
24. Nazário ACP, de Lima RG, Simões MJ, Novo NF: Cell Kinetics of the human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat 79(244): 23-27, 1995
25. Jordan VC, Collins MM, Rowsby L, Prestwich GA: Monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 75(2): 305-316, 1977
26. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32(9): 1031-1036, 1983
27. MacGregor SJ, Liu H, Bretrem DJ, Zapf JW, Jordan VC: Allosteric silencing of activating function 1 in the hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60(18): 5097-6105, 2000
28. Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW, Jordan VC: Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277(11): 9189-9198, 2002